drugset / Trial / NCT00880568
Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study determines recommended clinical dose, to evaluate the safety, tolerability and pharmacokinetics of MK-1496 in patients with locally advanced and/or metastatic solid tumors who have failed standard therapy or for whom no standard therapy exists, in two dosing schedules in Japan.
Timeline
- Start
- 2009-04
- Primary completion
- 2010-11
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-1496 | Small molecule | 20 mg | Oral |
| Subject | MK-1496 | Small molecule | 40 mg | Oral |
| Subject | MK-1496 | Small molecule | 80 mg | Oral |
| Subject | MK-1496 | Small molecule | 100 mg | Oral |
| Subject | MK-1496 | Small molecule | 120 mg | Oral |